Josephine Van Cauwenberge

Obesity➡️ worse prognosis & different biology #breastcancer. Still, BMI is only reported in 8% of 495 trials we reviewed. More research needed to study impact of BMI on treatment efficacy and toxicity🙏 ! @Josephine_VC @VanBaelenKaren @OncoAlert doi.org/10.1186/s13058…

Headed to another conference soon? Mobile data hassles are history thanks to Firsty! I've tried it in the USA: user-friendly and...it's free! Another way to continue our global dialogue! So proud to be on the sideline of this project! (firsty.app) #firsty

Our Lobular Breast Cancer Session #SABCS23 made possible by @SABCSSanAntonio and @AACR a wonderful foundation on which to build. Amazing team work #Globmob Thank you all for embracing our patient advocates involvement in your Research @elbcc @LobularBCA

Had a wonderful time at @SABCSSanAntonio 2023, proud to present my poster about the value of Mammaprint in clinical low risk patients. Also, very happy to see the extra attention for lobular breast cancer, let’s continue this effort 💪🏻 #SABCS23 #mammaprint

Proud to present this poster at the ILC symposium with @VanBaelenKaren. We’ve pointed out the lack of reporting of lobular breast cancer in recent drug trials #ILCSymposium @ChristineDesme2 @LobularBCA @elbcc

! ILC deserves much more attention from both clinical investigators and pharmaceutical industries! Very proud to present our poster on the lack of attention for ILC in clinical trials at #ESMOBreast2023. @Josephine_VC @ChristineDesme2 @LobularBCA @ELBCC

Proud to have presented our poster at #ESMOBreast2023, highlighting the lack of reporting BMI in recent breast cancer clinical trials. @VanBaelenKaren @ChristineDesme2